Subependymal Giant Cell Astrocytoma (SEGA): Management

Status: draft · Last updated 2026-11-17 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • Where and how often: at the foramen of Monro; found in 10–25% of TSC; more common with TSC2; median diagnosis at 8 years, but adults grow them too .
  • Acute hydrocephalus means surgery or CSF diversion.
    • Asymptomatic growth: everolimus is first-line for many. It gave a 50% or greater reduction in 35% at about 10 months and in 49% over the extension .
  • mTOR inhibitors must be continued: SEGAs regrow when they are stopped or underdosed .
  • LITT is an emerging middle path. In Dr. Hauptman's series, volume fell about 49% with few complications .
  • Every SEGA patient needs lifelong imaging surveillance.

Landmark papers

  • Krueger et al., N Engl J Med 2010: a prospective open-label phase 1/2 trial of everolimus for growing SEGA (28 patients). Volume fell by 30% or more in 75% at 6 months, and no one needed surgery .
  • EXIST-1 (Franz et al., Lancet 2013): a phase 3 randomized trial (117 patients). A 50% or greater SEGA reduction occurred in 35% with everolimus vs 0% with placebo .

In tuberous sclerosis complex (TSC), SEGA is the commonest CNS tumor. It is benign, but because it sits at the foramen of Monro it can cause obstructive hydrocephalus, which can be fatal .

The field has moved from "resect everything that grows" to a choice between three modalities:

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:sega:c1bc73ca4a09d24e© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Zoomed coronal section through the foramen of Monro with a lobulated SEGA from the caudothalamic groove obstructing the foramen and enlarging the ipsilateral ventricle, with the fornix, septum pellucidum, thalamostriate and internal cerebral veins labelled; transcallosal, transcortical, everolimus and laser ablation routes; and a decision panel(A) SEGA AT THE FORAMEN OF MONRO (CORONAL, ZOOMED)corpus callosumenlarged ipsilaterallateral ventricleseptum pellucidumSEGA: lobulated, enhancing,from the caudothalamicgroovecaudate headthalamostriate vein(at risk)fornix (at risk)internal cerebral vein(at risk)foramen of Monroobstructedthalamus(B) TREATMENT ROUTESopen transcallosalcorridoror transcortical(frontal, dotted)laser fiber andablation zone (LITT)oral everolimus≥50% volume reduction in 35% (EXIST-1),49% over extension; regrowth after stopping(C) CHOOSING A ROUTEacute hydrocephalus or large masssurgical resection (+/- CSF diversion)asymptomatic growth or multisystem diseasemTOR inhibitor (everolimus)not an mTOR candidate, no acute obstructionconsider laser ablation (LITT)
SEGA management. (a) Coronal view: SEGA arising from the caudothalamic groove at the foramen of Monro, obstructing the lateral ventricle, with subependymal nodules elsewhere. (b) Three treatment routes: open transcallosal or transcortical resection, oral mTOR inhibitor (everolimus) with tumor shrinkage, and stereotactic laser ablation along a trajectory to the lesion. (c) Decision factors: hydrocephalus or acute presentation, tumor size, seizure and systemic disease burden, tolerance and access to mTOR inhibitors. Not to scale.

Definition and natural history

Screening

Choosing treatment

mTOR inhibitors (everolimus, sirolimus)

Open and endoscopic surgery

Laser interstitial thermal therapy

Related topics

References

  1. Boop S, Bonda D, Randle S, et al. A comparison of clinical outcomes for subependymal giant cell astrocytomas treated with laser interstitial thermal therapy, open surgical resection, and mTOR inhibitors. Pediatr Neurosurg 2023;58(3):150–159. doi:10.1159/000531210. PMID 37232001. verified
  2. Northrup H, Aronow ME, Bebin EM, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol 2021;123:50–66. doi:10.1016/j.pediatrneurol.2021.07.011. PMID 34399110. verified
  3. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363(19):1801–1811. doi:10.1056/NEJMoa1001671. PMID 21047224. verified
  4. Roth J, Roach ES, Bartels U, et al. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. Pediatr Neurol 2013;49(6):439–444. doi:10.1016/j.pediatrneurol.2013.08.017. PMID 24138953. verified
  5. Jansen AC, Belousova E, Benedik MP, et al. Clinical characteristics of subependymal giant cell astrocytoma in tuberous sclerosis complex. Front Neurol 2019;10:705. doi:10.3389/fneur.2019.00705. PMID 31333563. verified
  6. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381(9861):125–132. doi:10.1016/S0140-6736(12)61134-961134-9). PMID 23158522. verified
  7. Dadey DY, Kamath AA, Leuthardt EC, et al. Laser interstitial thermal therapy for subependymal giant cell astrocytoma: technical case report. Neurosurg Focus 2016;41(4):E9. doi:10.3171/2016.7.FOCUS16231. PMID 27690646. verified
  8. Franz DN, Belousova E, Sparagana S, et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol 2014;15(13):1513–1520. doi:10.1016/S1470-2045(14)70489-970489-9). PMID 25456370. verified
  9. Tran LH, Zupanc ML. Long-term everolimus treatment in individuals with tuberous sclerosis complex: a review of the current literature. Pediatr Neurol 2015;53(1):23–30. doi:10.1016/j.pediatrneurol.2014.10.024. PMID 26092412. verified
  10. Weidman DR, Pole JD, Bouffet E, et al. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). Pediatr Blood Cancer 2015;62(10):1754–1760. doi:10.1002/pbc.25573. PMID 25929843. verified
  11. Hauptman JS. From the bench to the bedside: everolimus for subependymal giant cell astrocytomas in tuberous sclerosis complex, optic nerve regeneration, targeted cytotoxins for gliomas. Surg Neurol Int 2011;2:2. doi:10.4103/2152-7806.75587. PMID 21297924. verified

Verification (2026-11-17):

Caveats: